Physician profile
Michael Toye
NPI 1144746421
$5,886.58
in general payments reported to CMS, 2019-2025
36 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,223 · 2022: $983 · 2023: $1,076 · 2024: $1,175 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,680.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,635.13 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $795.03 | 2021-2025 | Belbuca, Xtampza |
| Pfizer INC. | $606.70 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $352.11 | 2021-2025 | Relistor |
| Orexo US, INC. | $276.07 | 2021-2025 | Zubsolv |
| Lundbeck LLC | $274.31 | 2023-2025 | Vyepti |
| Supernus Pharmaceuticals, INC. | $233.11 | 2021-2022 | |
| Axsome Therapeutics, INC. | $203.49 | 2025 | Symbravo |
| Biohaven Pharmaceuticals, INC. | $200.38 | 2021 | |
| Biodelivery Sciences International, INC. | $169.55 | 2021 | |
| Scilex Pharmaceuticals INC. | $160.77 | 2022-2024 | Ztlido |
| Biohaven Pharmaceutical Holding Company LTD. | $149.71 | 2022 | |
| Indivior INC. | $136.13 | 2021-2024 | Sublocade |
| Vertex Pharmaceuticals Incorporated | $104.16 | 2024-2025 | |
| Lilly USA, LLC | $94.61 | 2021-2023 | Emgality, Reyvow |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $93.17 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $44.65 | 2023 | Keveyis |
| Amgen INC. | $42.97 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $31.49 | 2021 | |
| Medtronic, INC. | $25.24 | 2022 | |
| Braeburn INC. | $22.91 | 2025 | Brixadi |
| Tonix Medicines, INC. | $20.31 | 2025 | Tonmya |
| Valinor Pharma, LLC | $19.42 | 2025 | Movantik |
| Averitas Pharma INC. | $19.36 | 2025 | Qutenza |
| Alkermes, INC. | $18.05 | 2025 | Vivitrol |
| Otsuka America Pharmaceutical, INC. | $16.84 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $16.70 | 2023 | Quviviq |
| Allergan, INC. | $16.14 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $15.83 | 2023 | Dysport |
| Merck Sharp & Dohme LLC | $15.44 | 2023 | Belsomra |
| Almatica Pharma LLC | $14.35 | 2021 | |
| Redhill Biopharma INC. | $13.92 | 2021 | |
| Uswm, LLC | $13.67 | 2021 | |
| G Medical Diagnostic Services, INC. | $11.99 | 2022 | |
| Grt US Holding, INC. | $11.58 | 2021 | |
| Hikma Pharmaceuticals USA | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Toye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.